ROCKVILLE, Maryland – October 15, 2009 – Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it expects to have top-line 52-week results available on Monday, November 2nd, from BLISS-76, the second of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in systemic lupus erythematosus (SLE).

Senior management will host a conference call to discuss the results on November 2, 2009 at 8:15 AM Eastern. The BLISS-76 data will later be submitted for full presentation at an appropriate scientific meeting.

Investors may listen to the call by dialing 800-753-9057 or 913-312-0718, passcode 9331404, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 9331404.

This conference call also will be webcast and may be accessed at www.hgsi.com.  Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS, Human Genome Sciences, and BENLYSTA are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of Human Genome Sciences’ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, Human Genome Sciences’ ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences’ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company’s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

###

Media Contact:
Jerry Parrott
Vice President, Corporate Communications
301-315-2777

Investor Contact:
Peter Vozzo
Senior Director, Investor Relations
301-251-6003